ID: ALA206740

Max Phase: Preclinical

Molecular Formula: C31H40N4O6

Molecular Weight: 564.68

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCC[C@H](NC(=O)O[C@@H]1C(=O)N(C(=O)NCCc2ccccc2)CC1(C)C)C(=O)C(=O)N[C@H](C)c1ccccc1

Standard InChI:  InChI=1S/C31H40N4O6/c1-5-6-17-24(25(36)27(37)33-21(2)23-15-11-8-12-16-23)34-30(40)41-26-28(38)35(20-31(26,3)4)29(39)32-19-18-22-13-9-7-10-14-22/h7-16,21,24,26H,5-6,17-20H2,1-4H3,(H,32,39)(H,33,37)(H,34,40)/t21-,24+,26-/m1/s1

Standard InChI Key:  GLOXJFDTZQXOJP-LJGDZFJRSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 564.68

Molecular Weight (Monoisotopic): 564.2948

AlogP: 3.91

#Rotatable Bonds: 12

Polar Surface Area: 133.91

Molecular Species: NEUTRAL

HBA: 6

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 10

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 12.24

CX Basic pKa:

CX LogP: 4.98

CX LogD: 4.98

Aromatic Rings: 2

Heavy Atoms: 41

QED Weighted: 0.33

Np Likeness Score: -0.28

References

1. Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Ray JA, Samano V, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL..  (2006)  Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.,  16  (6): [PMID:16376075] [10.1016/j.bmcl.2005.11.101]

Source

Source(1):

• Scientific Literature